-+ 0.00%
-+ 0.00%
-+ 0.00%

Inhibikase Therapeutics Q1 EPS $(0.10) Beats $(0.13) Estimate

Benzinga·03/26/2026 20:04:48
Listen to the news
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 33.33 percent increase over losses of $(0.15) per share from the same period last year.